Wells Fargo & Company Biomarin Pharmaceutical Inc Put Options Transaction History

Wells Fargo & Company

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 10, 2024	BUY	$83.81 - $99.0 $52.2 Million - $61.6 Million	622,500 New	622,500 $54.4 Million
Q1 2023 May 12, 2023	SELL	$87.74 - $117.27 $456,248 - $609,804	-5,200 Reduced 4.42%	112,400 $10.9 Million
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $6.75 Million - $8.43 Million	90,900 Added 340.45%	117,600 $9.07 Million
Q4 2020 Feb 09, 2021	BUY	$72.61 - $90.2 $624,446 - $775,720	8,600 Added 47.51%	26,700 $63,000
Q1 2020 May 14, 2020	BUY	$71.37 - $96.85 $1.29 Million - $1.75 Million	18,100 New	18,100 $148,000

635

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.